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Parkinson’s disease (PD) is characterized by loss of
A9 dopaminergic (DA) neurons in the substantia nigra
pars compacta (SNpc). An association has been re-
ported between PD and exposure to mitochondrial
toxins, including environmental pesticides paraquat,
maneb, and rotenone. Here, using a robust, patient-
derived stem cell model of PD allowing comparison
of A53T a-synuclein (a-syn) mutant cells and
isogenic mutation-corrected controls, we identify
mitochondrial toxin-induced perturbations in A53T
a-syn A9 DA neurons (hNs). We report a pathway
whereby basal and toxin-induced nitrosative/oxida-
tive stress results in S-nitrosylation of transcription
factor MEF2C in A53T hNs compared to corrected
controls. This redox reaction inhibits the MEF2C-
PGC1a transcriptional network, contributing to mito-
chondrial dysfunction and apoptotic cell death. Our
data provide mechanistic insight into gene-environ-
mental interaction (GxE) in the pathogenesis of PD.
Furthermore, using small-molecule high-throughput
screening, we identify the MEF2C-PGC1a pathway
as a therapeutic target to combat PD.
INTRODUCTION
Initial motor symptoms in Parkinson’s disease (PD) result from
loss of A9-type dopaminergic (DA) neurons in the substantia
nigra pars compacta (SNpc). Considerable damage occurs
before onset of clinical symptoms, making identification of early
events a challenge. Although the cause of sporadic PD is not fullyunderstood, various factors, including environmental toxins,
have been implicated. Mitochondrial toxins have been identified
in epidemiological studies as contributing to ‘‘sporadic’’ PD,
and mitochondrial-based toxin models gained attention follow-
ing the discovery of MPTP-induced Parkinsonism (Langston
et al., 1983). Paraquat (PQ; 1, 10-dimethyl-4,40-bipyridinium), a
commonly used herbicide, shares structural similarity with
MPP+, the active metabolite of MPTP. PQ crosses the blood-
brain barrier, generates reactive oxygen and nitrogen species
(ROS/RNS) and causes loss of SNpc DA neurons in animal
models (Shimizu et al., 2001; Bonneh-Barkay et al., 2005; Mora´n
et al., 2010). Additional pesticides, including the fungicide
maneb (MB; manganese ethylnebisdithiocarbamate) and the
insecticide rotenone, can induce neuronal death in PD models.
Human epidemiological studies show association of PQ/MB
exposure to development of PD (Costello et al., 2009), and this
combination causes PD in animal models (Thiruchelvam et al.,
2000). Though the contribution of pesticides to sporadic PD
remains contentious, involvement of mitochondria is generally
accepted. Thus, these toxins are used in disease models to
induce mitochondrial electron transport chain dysfunction and
related cell injury.
In contrast to sporadic PD, rare familial forms are causally
linked to genetic mutations that are either dominant (PARK3,
LRRK2, UCH-L1, PARK13, and SNCA [encoding a-syn]) or
recessive (Parkin, PINK1, FBXO7, PLA2G6, and PARK9). Some
gene products, including a-syn, contribute to aggregate forma-
tion in PD, appearing as intracellular inclusions (Lewy bodies
and neurites). PD-associated gene mutations have been used
to generate animal models to study the molecular basis of PD
pathogenesis. Two categories of cellular events have been
uncovered in these studies: (1) protein misfolding, aggregation,
and aberrant proteostasis and (2) mitochondrial damage with
oxidative/nitrosative stress (Dauer and Przedborski, 2003).Cell 155, 1351–1364, December 5, 2013 ª2013 Elsevier Inc. 1351
Figure 1. Characterization of hiPSC Differentiation into A9-type DA Neurons
(A) Micrographs of hiPSC differentiation into human DA neurons (hNs). NPCs (top) are both FOXA2/LMX1A double positive and OTX2/FOXA2 double positive
at 11 days in vitro (DIV). Most b-III tubulin (TUJ1)+ neurons (lower-middle) stain for TH by DIV 25. TH+ neurons are also LMX1A+, NURR1+ (upper-middle) and
GIRK2+ (bottom) at DIV 35. Blue, DAPI; scale bar, 50 mm.
(B) Quantification of TUJ1, TH/TUJ1, TH/LMX1A, and TH/GIRK2-positive cells relative to total cell number. Data from replicate experiments at DIV 35 are shown
as mean + SEM; n = 6.
(C–E) Electrophysiological characterization of A53T hNs and corrected controls at DIV 35. INa and IK traces (n = 30, C). Cells were prepulsed to90mV for 150ms
and held at 60 mV with 10 mV voltage steps. Evoked action potential trains (Vh = 70 mV, n = 30, D). Spontaneous action potentials (n = 8, E). Mean resting
potential, 39 ± 6 mV for A53T hN and 40 ± 3 mV (mean ± SEM) for corrected hN. Electrophysiological recordings were performed using K-gluconate internal
solution.
(F) a-synuclein costaining with thioflavin T in hiPSC-derived corrected (Corr) and A53T hNs. A53T mutant shows increased thioflavin T. DIV, 35; blue, DAPI;
scale bar, 10 mm.
(legend continued on next page)
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Identifying pathways that link these events could provide infor-
mation regarding events that lead to death of SNpc DA neurons.
Recently, nitrosative/oxidative stress was reported to lead
to tyrosine nitration and methionine oxidation on a-syn, thus
contributing to aggregation (Giasson et al., 2000; Schildknecht
et al., 2013; Chavarrı´a and Souza, 2013). Considering the
association of mitochondrial toxins with PD, another key ques-
tion concerns interactions between environmental and genetic
factors in PD. In fact, animal models suggest that PQ/MB ren-
ders mutant A53T a-syn transgenic mice particularly vulnerable
to PD-like pathology (Norris et al., 2007). Cell-based studies on
human tissue could potentially identify early molecular events
linking environmental and genetic factors in PD.
Recent advances in human induced pluripotent stem cell
(hiPSC) technology provide an opportunity to study these events
in human context (Takahashi and Yamanaka 2006; Saha and
Jaenisch 2009). Recently, this technology was used to generate
hiPSC models of PD patients’ cells carrying disease-causing
mutations (Nguyen et al., 2011; Cooper et al., 2012). These
models recapitulate key features of PD and validate the feasi-
bility of using hiPSCs to model the disease. However, lack of
genetically matched nondiseased controls makes interpretation
of observed phenotypes difficult to attribute solely to the
disease-causing mutation. This confounding variable must be
overcome, as differences in genetic background between cell
types may critically influence data interpretation. Moreover, the
relevance of findings from the above studies to PD is further
undermined by limited representation of A9-type DA neurons
following differentiation of hiPSCs to neurons.
Two recent events have allowed us to resolve the above
issues. First, we generated isogenic stem cell models of PD
(Soldner et al., 2011) in which we ‘‘correct’’ a SNCA-A53T
mutation in patient-derived hiPSCs or ‘‘knock in’’ the same
mutation in a human embryonic stem cell (hESC) line. This results
in two pairs of isogenic stem cells that differ exclusively at the
SNCA locus that can be used to study PD. Second, nearly
pure populations of A9-type DA neurons can now be generated
from pluripotent cells (Kriks et al., 2011). By combining these
two methods, we tested a ‘‘multi-hit’’ scenario whereby mito-
chondrial toxins and cellular genetic factors interact in PD
pathology. We report here a molecular pathway whereby
increased basal and mitochondrial toxin-induced nitrosative
stress results in inhibition of transcriptional activity of myocyte
enhancer factor 2C (MEF2C) in A53T a-syn mutant A9 DA
neurons (hNs) compared to corrected controls. We validate
these findings using two distinct isogenic lines, representing
both hiPSCs and hESCs, with disparate genetic backgrounds.
Because MEF2C activity normally stimulates transcription of
peroxisome proliferator-activated receptor-g coactivator-1a
(PGC1a), inhibition of MEF2C decreases this neuroprotective
pathway. Disruption of the MEF2C-PGC1a pathway contributes
to mitochondrial dysfunction and culminates in apoptotic cell(G) Quantification of thioflavin T fluorescence. Data from replicate experiments a
(H and I) Immunostaining of corrected hNs (H) and A53T mutant hNs (I) shows
(arrows). DIV, 35; blue, DAPI; scale bar, 10 mm.
See also Figure S1 and Table S1.death. Our results identify redox-mediated protein posttransla-
tional modifications, including S-nitrosylation and sulfonation
of a critical cysteine residue in MEF2, as an early event contrib-
uting to neuronal damage in PD. Screening for small molecules
that rescue neurons from thesemitochondrial toxins, we validate
the MEF2C-PGC1a pathway as a new drug target for PD.
RESULTS
A9 Dopaminergic Neurons Derived from A53T
Mutant hPSCs Display a-Syn Aggregation
and Lewy Body/Neurite-like Pathology
Using hiPSCs that allow comparison of the A53T a-syn mutation
(A53T) with isogenic-corrected controls (Corr) (Soldner et al.,
2011), we characterized the lineage progression of hiPSCs to
dopaminergic (DA) neurons. To determine the impact of the
A53T a-syn mutation on cellular pathology in PD, it was critical
to generate the specific cell type affected in PD, A9 dopami-
nergic (DA) neurons. Using the protocol of Kriks et al. (2011),
we differentiated hiPSC into A9 DA neurons with high efficiency
(80% of total neurons) from both mutant A53T and corrected
hiPSCs (Figures 1A–1E). Neurons progressed from hiPSCs to
forkhead box A2 (FOXA2)+/LIM homeobox transcription factor
1a (LMX1A)+ or OTX2+ neural progenitor cells (NPCs). Next,
upon terminal differentiation, they progressed to LMX1A+/tyro-
sine hydroxylase (TH)+, nuclear-receptor-related 1 protein
(NURR1)+/TH+, or G-protein-regulated inward-rectifier potas-
sium channel 2 (GIRK2)+/TH+ neurons (Figures 1A and 1B).
Electrophysiological characterization of hNs revealed voltage-
dependent sodium currents (Figure 1C) and evoked action
potentials (Figure 1D). Moreover, spontaneous, rapid (2–7 Hz)
spikes, a hallmark of the A9 DA neuronal phenotype and consis-
tent with the presence of CaV1.3 channels (Kriks et al., 2011),
were observed by day 35 of terminal differentiation in hiPSC-
derived hNs (Figure 1E). Electrophysiological parameters are
listed in Table S1 available online. Additionally, we confirmed
these results in a second set of isogenic PSC-derived neurons
of disparate genetic background obtained from wild-type (WT)
and A53T-mutated hESCs (Soldner et al., 2011) (Figures S1A
and S1B, available online). These hNs also displayed voltage-
dependent sodium currents (Figure S1C) and spontaneous,
rapid action potentials (Figure S1D) comparable to those of their
hiPSC-derived counterparts.
A53T mutation induces a-syn aggregation into oligomeric b
sheets, which result in deposition in Lewy bodies/neurites. We
thus assessed whether basal synuclein pathology could be
detected in A53Tmutant hNs. Costaining for thioflavin T and total
a-syn showed a dramatic increase in thioflavin T fluorescence
that colocalized with a-syn in A53T hNs relative to corrected
hNs, indicating accumulation of oligomerized a-syn (Figures 1F
and 1G). We next confirmed Lewy body/neurite-like a-syn
deposition using an alternative antibody approach to detectt DIV 35 shown as mean + SEM; n = 3.
PS-129 colocalization with ubiquitin in neurites and cell bodies of A53T hNs
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phosphorylation of a-syn on serine 129 (Wang et al., 2012). Anti-
genic labeling of a-syn phosphoserine (PS)-129 and ubiquitin
again revealed Lewy neurite/body-like deposition in A53T, but
not corrected hNs (Figures 1H and 1I). Immunoblots also showed
elevated a-syn PS129 levels in A53T relative to corrected hNs
(Figure S1E). Whereas a-syn protein levels were higher in A53T
compared to control hNs from both isogenic lines (Figures S1E
and S1F), allele-specific PCR revealed no difference in SNCA
mRNA expression (Figures S1G–S1I). Additionally, qRT-PCR of
hiPSC-derived A53T and corrected hNs revealed no quantitative
difference in SNCA mRNA expression (1.0 versus 1.1 arbitrary
units). Taken together with prior work, these data suggest that
synuclein pathology is associated with increased a-syn stability
in A53T hNs, similar to A53T a-syn mouse models and human
PD brain (Li et al., 2004; Wills et al., 2010).
A53T a-Syn Mutant hNs Manifest Alterations in Basal
Mitochondrial Machinery and Increased Susceptibility
to Mitochondrial Toxins
The presence of a-syn aggregates in A53T hNs under basal
conditions led us to investigate other PD-relevant pathologies.
For example, deficits in mitochondrial respiration are critically
associated with neuronal dysfunction in PD. Therefore, we eval-
uated mitochondrial function in both A53T mutant and corrected
hNs. Using the Seahorse platform to measure O2 consumption,
we found a compromised maximal rate of mitochondrial respira-
tion in A53T compared to corrected hNs (Figures 2A and 2B),
resulting in deficiency in spare respiratory capacity (50% versus
190% for A53T and corrected hNs, respectively). We thus
assessed the ability of A53T mutant versus corrected hNs to
respond to stress induced by mitochondrial toxins known to
affect neuronal viability.
Apoptosis was scored by TUNEL assay coupled with nuclear
morphology or cleaved caspase-3 immunoreactivity. Choosing
concentrations based on the EPA-reported lowest observable
effect level (LOEL) (http://www.epa.gov/iris/subst/0183.htm),
we determined the apoptotic index of the PD-associated pesti-
cides PQ and MB alone and in combination, as well as that of
rotenone in corrected and A53T mutant hNs (Figures 2C–2F,
S2A, and S2B). These pesticides function in part by inhibiting
mitochondrial respiratory chain complexes I (PQ and rotenone)
or III (MB) (Gomez et al., 2007). A53T mutant hNs relative to
corrected control manifested increased susceptibility to toxin
mediated-apoptosis. Interestingly, combined exposure of
A53T mutant hNs to PQ/MB produced synergistic effects,
decreasing the concentration of each toxin required to evoke
death (Figures 2E and 2F). At 2.8 mM PQ and 1 mM MB,
differential susceptibility to toxin-evoked death was observed
between A53T mutant and corrected hNs. This differential
susceptibility was also observed in hESC-derived WT and
A53T mutant hNs (Figures S2C and S2D). Although a-syn
expression and phosphorylation on serine 129 were greater in
A53T hNs, mitochondrial toxins had no additional effect on
a-syn expression or aberrant phosphorylation. We next sought
to understand this differential susceptibly to mitochondrial
toxins by profiling changes in gene expression to identify sig-
naling pathway(s) that are aberrantly regulated in A53T mutant
hNs versus corrected controls.1354 Cell 155, 1351–1364, December 5, 2013 ª2013 Elsevier Inc.Aberrant Modification of MEF2C by Oxidative/
Nitrosative Stress in A53T Mutant Neurons
We used global gene expression analysis via microarray to
identify biological processes specifically altered under basal
conditions in A53T versus corrected hNs (Figure 3A). Enrichment
analysis based on Gene Ontology (GO) revealed a decrease in
expression of prosurvival genes and genes associated with
metabolic function (Figure S3A). Next, we screened regulatory
networks of multiple transcription factors against our microarray
data set to identify factors whose target gene sets were sig-
nificantly altered (p < 0.05) in A53T hNs relative to corrected.
Based on GO analysis, we prioritized transcription factors with
known functions related to apoptosis (Figure 3B), cell survival
(Figure 3C), and DA neuron-specific transcriptional regulation
(Figure 3D). We found that transcription factors whose targets
are involved in DA neuron regulation were highly enriched
among downregulated genes in A53T hNs, with the prosur-
vival/neurogenic transcription factor MEF2 (Leifer et al., 1993;
Mao et al., 1999; Okamoto et al., 2000, 2002) being most
enriched. MEF2 protein levels, however, showed little difference
between A53T and corrected hNs (Figure S3B). We thus sought
to determine how A53T SNCA mutation or mitochondrial
stress might affect MEF2 transcriptional activation. We initially
focused on MEF2C because it is the predominant isoform
expressed in hPSCs developing into brainstem SNpc neurons
(Lyons et al., 1995; Cho et al., 2011).
One indication of mitochondrial stress, particularly after inhi-
bition of complex I, is increased ROS production. Via MitoSOX
fluorescence, we monitored superoxide anion, an indicator of
ROS load, and found increased levels in A53T hiPSC-derived
hNs relative to corrected both at baseline and following expo-
sure to mitochondrial toxins (Figures 4A and 4B). We found a
similar increase in basal MitoSOX fluorescence in A53T mutant
human neurons derived from hESCs relative to isogenic WT
controls (Figure S4A). ROS-induced posttranslational protein
modifications can affect functional activity via reaction to a sul-
fonated adduct (Gu et al., 2002). To determine whether MEF2C
can be so modified, we performed mass spectrometry (MS) on
recombinant MEF2C following H2O2 exposure and detected
a sulfenated (SO) derivative, indicated by a 16 Da shift
in the MEF2C mass (Figure S4B). To identify the modified
cysteine residue, we used DCP-Bio1 to detect sulfenated
(SOH) derivatives after exposure to H2O2. MS/MS on the
DCP-Bio1 labeled-protein identified cysteine (Cys39) in the
DNA-binding domain of MEF2C as the sulfenated site (Fig-
ure S4C). Next, we probed intact cells for SOH-MEF2C using
the –SOH-specific detection technique of DCP-Bio1—assisted
capture followed by immunoblot (Figures 4C and 4D) (Nelson
et al., 2010). We found no substantial difference in SOH-
MEF2C under basal conditions in A53T hNs relative to cor-
rected controls but observed a dramatic induction after
exposure to either H2O2 or PQ/MB. Additional MS experiments
performed in the absence of DCP-Bio1 revealed higher oxida-
tion states of the protein (representing SO2/3H derivatization),
often achieved in the presence of high ROS levels (Gu et al.,
2002). Taken together, these experiments show that exposure
to excessive ROS leads to the formation of SOxH-MEF2C
(wherein x = 1–3).
Figure 2. A53T Mutant hNs Are Highly Sus-
ceptible to Mitochondrial Toxin-Induced
Apoptosis
(A and B) Mitochondrial O2 consumption monitored
by Seahorse platform at DIV 35. After recording
basal respiration, mitochondrial metabolic state 4
was induced with 1 mg/ml of the ATP synthase in-
hibitor oligomycin (Oligo), followed by induction of
maximal respiration by themitochondrial uncoupler
FCCP in 1.5 mM increments. Maximal (Max) respi-
ration was attained at a total FCCP concentration of
4.5 mM. Data from one of three replicate experi-
ments are shown as mean ± SEM; n = 22 wells (A).
Experimental data normalized to cell number per
well (B). Neither basal respiration (reflecting cellular
ATP demand) nor state 4 respiration (reflecting
proton leak) differed between control and mutant
cells. A53T mutant hNs displayed greatly reduced
maximal respiratory capacity compared to cor-
rected control.
(C–E) A53T mutant hNs are more susceptible to
apoptosis than their genetically corrected coun-
terparts following exposure to PQ alone (C), MB
alone (D), or combined exposure (E). Data repre-
sent mean + SEM. **p < 0.01 by ANOVA with
posthoc Tukey; n = 6–12; DIV, 35.
(F) Micrographs of TUNEL+ hNs following mito-
chondrial toxin exposure. DIV, 35; blue, DAPI; scale
bar, 10 mm.
See also Figure S2.
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Figure 3. A53T Mutant hNs Manifest Altered Transcriptional
Network Activity
(A) Expression profiling of A53T mutant and corrected (Corr) hNs at DIV 35.
Genes whose expression was altered R 2-fold (p < 0.05 significance) were
clustered based upon functional correlation using GenePattern (Broad
Institute), and the resulting heatmap is depicted (red, up; blue, down; data
from three replicate experiments). A53T mutant hNs had a strikingly different
genetic profile from corrected counterparts.
(B–D) Pathway enrichment analysis was performed on all genes whose
expression was altered (7,018 genes; p < 0.05 significance) in A53T hNs
relative to corrected using NextBio and was filtered based on regulatory motifs
using the Broad Institute Molecular Signatures Database (BroadMSigDB).
Enrichment score was assigned by NextBio based on the method of
Kupershmidt et al. (2010). Transcription factors were grouped based on their
contribution to apoptosis (B), cell survival (C), or DA neuronal transcription (D).
Transcription factor with the highest enrichment score was MEF2 (denoted in
red). (Blue circle) Genes altered in A53T relative to corrected; (red circle) genes
with transcription factor binding motifs within 2 kb of the transcriptional start
site; (purple overlap) genes with transcription factor binding motifs within 2 kb
of the transcriptional start site that are altered in A53T relative to corrected.
See also Figure S3.In addition to ROS, RNS such as nitric oxide (NO) have been
linked to mitochondrial stress and can react with critical
cysteine residues to affect functional activity via protein S-nitro-
sylation (forming SNO proteins) (Lei et al., 1992; Lipton et al.,
1993; Stamler et al., 1992, 1997). NO can also react rapidly
with superoxide anion (O2
) to form peroxynitrite (ONOO),
causing tyrosine nitration and contributing to protein aggrega-
tion in the case of a-syn (Giasson et al., 2000). Using the NO-
sensitive dye DAF-FM, we found an increase in basal levels of
NO in A53T mutant hNs derived from both PSC lines compared
to their respective controls (Figures 4E and 4G, inset, and Fig-
ure S4D). Interestingly, low-dose mitochondrial toxins (2.8 mM
PQ/1 mM MB) resulted in further accumulation of NO only in
A53T mutant and not in corrected hNs (Figures 4F and 4G).
Monitoring NO production via Griess reaction to measure the
metabolite nitrite, we found that prolonged exposure to a higher
dose of PQ/MB (28 mM/5 mM) also evoked NO accumulation in
A53T-corrected hNs (Figure S4E). This increase in NO produc-1356 Cell 155, 1351–1364, December 5, 2013 ª2013 Elsevier Inc.tion both basally and following exposure to PQ/MB was
blocked by pretreatment with the NO synthase (NOS) inhibitor
L-NG-nitroarginine methyl ester (L-NAME), confirming that the
increase in DAF-FM fluorescence was most likely due to NO
(Figures 4H and S4F).
Next, we performed MS experiments to determine whether
MEF2C can also be modified by S-nitrosylation. After exposing
recombinant MEF2C to endogenous NO donor S-nitrosocys-
teine (SNOC), MS/MS revealed that MEF2C can indeed be
S-nitrosylated, and this modification occurs on the same candi-
date cysteine (Cys39) as sulfonation (Figure S4G). Cys39 is
located in the DNA-binding domain of MEF2C (Huang et al.,
2000; Santelli and Richmond, 2000), suggesting that these
posttranslational redox modifications might inhibit MEF2 tran-
scriptional activity. Hence, we constructed a nonnitrosylatable/
nonsulfonatable MEF2C mutant (MEF2C(C39A)), permitting us
to test whether such redox reactions are causally linked to
aberrant transcriptional activity and neuronal cell death.
To determine whether SNO-MEF2C is produced in neurons
under basal conditions or following exposure to mitochondrial
toxins, we probed A53T mutant and corrected hNs for S-nitrosy-
lated MEF2C using the biotin switch assay. We found that
A53T mutant hNs have high basal levels of SNO-MEF2C relative
to corrected controls (Figures 4I–4K), suggesting that this was
an aberrant modification existing under baseline conditions in
A53T hNs. We found higher basal levels of SNO-MEF2C in our
second set of isogenic A53T mutant hNs as well (Figure S4H).
Additionally, high-dose PQ/MB exposure promoted SNO-
MEF2C formation in corrected hNs (Figures 4I and 4K). Pretreat-
ment with L-NAME prevented this modification in both A53T
hNs under basal conditions and in corrected hNs after exposure
to pesticides (Figures 4J and S4I).
Formation of SNO-MEF2C Inhibits Transcription
of the Mitochondrial Master Regulator PGC1a
We next sought to determine whether redox modification of
MEF2C could inhibit its transcriptional activity and, if so, to iden-
tify which transcriptional targets were altered in A53T hNs to
account for increased neuronal susceptibility after mitochondrial
stress. We performed both western blot and quantitative (q) real-
time PCR analysis of MEF2C-regulated genes of importance
to development or survival of A9 DA neurons. In A53T mutant
hNs relative to control, we found decreased protein expression
of the MEF2C transcriptional target NURR1 and the NURR1
transcriptional target TH, proteins highly enriched in A9 DA
neurons (Figure 5A). Further analysis of mRNA levels showed
decreased mRNA expression of MEF2-regulated genes, includ-
ingmicrotubule-associated protein 2 (MAP2), encoding a neuro-
nally restricted protein, and PGC1a, a transcriptional coactivator
that is known to promote neuroprotection in PD models (Figures
5B and 5C) (Clark and Simon, 2009). Consistent with the
microarray, we also found altered mRNA expression of the
MEF2 transcriptional target GLDC (a mitochondrial glycine
decarboxylase), whereas other markers of the A9 phenotype
(GIRK2 and PITX3) were unchanged (Figure S5A). Importantly,
treatment with L-NAME promoted mRNA expression of multiple
MEF2 targets (Figure S5B). Although several of these targets are
important for DA neurons, we identified PGC1a as a critical
effector of MEF2, given its importance in mitochondria and in
PD models (Jones et al., 2012).
To assess involvement of MEF2C in PGC1a signal transduc-
tion, we first performed a reporter assay to determine whether
MEF2C directly regulates PGC1a expression. We examined
PGC1a promoter activity under normal conditions and after
mutation of the MEF2-binding site (DMEF2-PGC1a) and found
a significant decrease in normal WT-PGC1a promoter activity
in A53T hNs relative to corrected. Whereas DMEF2-PGC1a
reduced PGC1a promoter activity in corrected hNs, the effect
was minimal in A53T cells, indicating that MEF2 was already
inhibited (Figure 5D). L-NAME significantly prevented this inhi-
bition on WT-PGC1a promoter (Figure 5E). Taken together,
these findings suggest that decreased MEF2 activity contributes
to inhibition of PGC1a expression, and NO is a critical factor in
this inhibition.
To determine whether the basal level of redox-modified
MEF2C in A53T mutant hNs interferes with MEF2C binding
to the PGC1a promoter, we performed chromatin immuno-
precipitation (ChIP) of MEF2C on the PGC1a promoter in
both A53T hNs and corrected controls. We found a 75%
reduction in MEF2C bound to PGC1a promoter in A53T mutant
hNs (Figure 5F). We confirmed that MEF2 binding to the
PGC1a promoter was NO dependent by treating A53T mutant
hNs with L-NAME, finding a 10-fold increase in bound MEF2C
(Figure 5G). To show that the decrease in PGC1a promoter
activity was due specifically to S-nitrosylation of MEF2C on
Cys39, we overexpressed both WT and nonnitrosylatable
MEF2 mutant (MEF2C(C39A)) in corrected and A53T mutant
hNs. Overexpression of WT MEF2C in A53T mutant hNs was
50% less effective than in corrected hNs in driving PGC1a
promoter activity, presumably due to the high basal levels
of NO that are present in A53T hNs. Transfection with nonnitro-
sylatable MEF2C prevented the decrease in MEF2 transcrip-
tional activity observed under basal conditions or following
exposure to NO-generating agents (Figure 5H). Interestingly,
MEF2C(C39A) expression resulted in higher basal levels of
PGC1a promoter activity in A53T hNs than their corrected
counterparts, presumably due to an effect on other MEF2
regulators such as HDAC9, which was downregulated on our
microarray.
Next, to determine whether SNO-MEF2C-dependent loss of
PGC1a expression could be observed in vivo, we administered
intraperitoneal PQ/MB to adult WT and A53T mutant mice.
A53T mutant mice manifested a decrease in basal levels of
PGC1a protein expression relative to WT (Figure 6A). This loss
of PGC1a expression was exacerbated in both WT and A53T
mutant animals following exposure to PQ/MB. Moreover, PQ/
MB resulted in substantial increase in SNO-MEF2C, detectable
up to 4 weeks postadministration (Figures 4B and 4C). In
addition, we found markedly reduced PGC1a protein levels in
mouse brains from MEF2C global heterozygotes or Nestin-
Cre-driven brain-specific knockout (Li et al., 2008a) (Figure 5E).
Collectively, these data show that MEF2C can be S-nitrosylated
or sulfonated by RNS/ROS at Cys39 and raise the possibility
that this reaction can result in negative regulation of MEF2C
transcriptional activity in the context of PD. Moreover, the results
implicate loss of MEF2 transcriptional activity and thus failureto induce neuroprotective PGC1a expression as an effector of
nitroxidant stress in A9 DA neurons.
Preventing S-Nitrosylation and Promoting
MEF2C-PGC1a Transcriptional Activity
Rescue A53T Mutant hNs from Death
We assessed whether pretreatment with L-NAME to inhibit
S-nitrosylation, with consequent enhancement of the MEF2C-
PGC1a transcriptional pathway, would offer therapeutic benefit
in A53T hNs exposed to mitochondrial toxins. Indeed, L-NAME
partially rescued A53T mutant hNs derived from both PSC
lines from pesticide-induced death (Figures 7A, S6A, and S6B).
L-NAME also conferred partial protection to corrected hNs
exposed to high-dose PQ/MB (Figure S6C). Because inhibiting
NO synthesis conferred protection from cell death, we next
sought to determine whether genetic rescue of MEF2C-PGC1a
activity could promote cell survival. Although we found that
overexpression of WT MEF2C was able to partially rescue
(64%) from PQ/MB toxin-induced death in A53T mutant hNs,
the nonnitrosylatable/nonsulfonatable MEF2C(C39A) provided
significantly more neuroprotection (83%) (Figures 7B and 7C).
Interestingly, this level of protection was similar to that observed
with overexpression of WT MEF2C in conjunction with L-NAME
treatment (81%) (Figure 7C). The nonredox-modifiable MEF2C
mutant also rescued from toxin-induced death in our second
set of isogenic PSCs, with greater efficacy than WT MEF2C
(Figures S6D and S6E). The fact that mutant MEF2C(C39A) pro-
vided the greatest degree of neuroprotection frommitochondrial
toxins and that this level of protection was similar to that seen
with WT MEF2C plus L-NAME is consistent with the notion that
S-nitrosylation of Cys39 by the toxins inhibited MEF2C activity,
thus contributing to cell death. To gather further evidence for
the importance of the MEF2C-PGC1a pathway in protecting
hNs from mitochondrial stress, we next assessed whether
PGC1a could directly rescue from PQ/MB-mediated apoptosis.
In fact, we observed that overexpression of PGC1a nearly
completely abrogated mitochondrial toxin-induced apoptosis
(93% reduction in death) (Figures 7B and 7C).
In our final set of experiments, aimed at developing a therapeu-
tic, weperformed high-throughput screening (HTS) for smallmol-
ecules capable of targeting the MEF2C-PGC1a pathway.
We screened a chemical library of compounds for their ability
to activate MEF2 transcription in the human neuronal context.
One molecule identified was isoxazole (Figure S6F), consistent
with previous results in rodent cells (Schneider et al., 2008). We
thus assessed isoxazole as a potential therapeutic in
A53T mutant hNs. Isoxazole effectively drove expression of
both MEF2C and PGC1a in A53T hNs (Figure S6G). Moreover,
isoxazole protected A53T hNs from apoptosis induced by the
mitochondrial toxins rotenone or PQ/MB (Figures 7D and 7E). In
summary, these data identify a pathway common to both
genetic and environmental stress in PD centered on ROS/RNS-
mediated repression of the MEF2C-PGC1a transcription path-
way. This pathway can be therapeutically targeted to promote
survival of human A9 DA neurons derived from PD patients
(Figure 7F). Moreover, because several FDA-approved drugs
contain isoxazole rings, our findings may have potential clinical
implications for the repurposing of known drugs to treat PD.Cell 155, 1351–1364, December 5, 2013 ª2013 Elsevier Inc. 1357
Figure 4. Accumulation of ROS/RNS in A53T hNs Aberrantly Modifies the Neuronal Prosurvival Transcription Factor MEF2C
(A) Representative micrographs of MitoSOX (red)-labeled A53T mutant and corrected hNs superimposed on phase-contrast images under basal conditions. DIV,
35; blue, DAPI; scale bar, 10 mm.
(B) Quantification of superoxide anion accumulation at DIV 35 in corrected and A53T mutant hNs measured via MitoSOX labeling following pesticide exposure.
A53T mutant hNs displayed increased labeling relative to corrected (Corr) at baseline and following exposure to 200 nM rotenone or 2.8 mMPQ/1 mMMB. Values
are mean + SEM. **p < 0.01 by t test; n = 6.
(C) Increased SOH-MEF2C detected at DIV 35 in A53T relative to corrected hNs after administration of mitochondrial toxins. SOH-protein capture using DCP-
Bio1 and subsequent immunoblot for MEF2C show increased SOH-MEF2C upon exposure to H2O2 or PQ/MB.
(D) Quantification of SOH-MEF2C. Values are mean + SEM. *p < 0.05 by ANOVA with posthoc Tukey; n = 3.
(E and F) DAF-FM staining of NO levels shows higher basal values and more rapid accumulation of NO after pesticide exposure in A53T mutant relative to
corrected hNs.
(G) Time course of DAF-FM signal in A53T and corrected hNs following exposure to PQ/MB normalized to respective baseline levels. Inset shows that A53T
mutant hNs have a 17% higher level of DAF-FM fluorescence than corrected hNs at baseline.
(H) L-NAME pretreatment reduced both baseline and pesticide-evoked DAF-FM signal in A53T hNs. Pesticide exposure time, 6 hr; DIV, 35; blue, DAPI; scale bar,
10 mm. Data represent mean ± SEM. **p < 0.01 by two-way ANOVA with posthoc Tukey; n = 6.
(legend continued on next page)
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Figure 5. MEF2C-Mediated Transcriptional Activation Is Inhibited in A53T hNs
(A) Immunoblot analysis shows decreased TH and NURR1 protein expression in A53T mutant relative to corrected hNs at DIV 35.
(B and C) qRT-PCR shows significant reduction in MAP2 and PGC1a mRNA in A53T mutant relative to corrected hNs at DIV 35. Data represent mean + SEM.
**p < 0.01 by t test; n = 3.
(D) Activation of native PGC1a promoter and PGC1a promoter lacking the MEF2-binding site (DMEF2) in A53T hNs relative to corrected hNs at DIV 35. Data
represent mean + SEM. **p < 0.01 by t test; n = 4.
(E) MEF2-driven PGC1a promoter activity inhibited in A53T hNs relative to corrected hNs at DIV 35. L-NAME prevented 50% of this inhibition. PGC1a promoter
activity attributable to MEF2 was derived from the following formula using the data in (D): (1 – (DMEF2/PGC1a)3 100). Data represent mean + SEM. **p < 0.01 by
t test; n = 4.
(F) ChIP analysis on chromatin prepared from A53T mutant versus corrected (Corr) hNs at DIV 25 revealed 4-fold reduction in MEF2C bound to PGC1a promoter.
Data represent mean + SEM. *p < 0.05 by t test; n = 3.
(G) L-NAME increases MEF2C binding to PGC1a promoter by 10-fold. Data represent mean + SEM. **p < 0.01 by t test; n = 3.
(H) Effect of WT MEF2C or mutant MEF2C(C39A) on PGC1a promoter activity in the presence and absence of SNOC in A53T and corrected hNs at DIV 35.
Data represent mean + SEM. *p < 0.05 by ANOVA with posthoc Tukey; n = 4.
See also Figure S5.DISCUSSION
SNpc A9-type DA neurons are known to possess a unique form
of pacemaking activity that can produce Ca2+ overload, which
has been implicated in both mitochondrial and endoplasmic re-
ticulum (ER) stress; the associated increase in ROS/RNS may
contribute to a-syn-dependent cell death in PD (Mosharov
et al., 2009; Guzman et al., 2010). Given the high energy de-
mands of neurons in general and the pacemaking activity of A9
neurons in particular, it is not surprising that these cells display
increased dependence on mitochondrial respiration. Compro-
mised mitochondrial function can thus be devastating to these
neurons. Here, we show that hiPSC-derived A9 DA neurons(I and J) Biotin switch at DIV 35 shows that A53T mutant hNs had substantial b
SNO-MEF2C levels (I), and L-NAME inhibited basal SNO-MEF2C formation with
(K) Quantification of SNO-MEF2C. Values are mean + SEM. **p < 0.01, by ANOV
See also Figure S4.bearing the A53T SNCA mutation exhibit diminished mitochon-
drial spare-respiratory capacity and produce increased basal
levels of ROS/RNS compared to isogenic corrected controls.
Moreover, we find that even brief exposure to mitochondrial
toxins is sufficient to further increase ROS/RNS, contributing
to neuronal damage. We observed that administration of
commonly used pesticides at doses below EPA-accepted levels
is sufficient to inflict oxidative/nitrosative stress and consequent
death in these hiPSC-derived A9 neurons. Increased susceptibil-
ity of hiPSC-derived neurons with the A53T SNCAmutation likely
reflects the fact that these mutant cells manifest increased basal
levels of ROS/RNS compared to isogenic corrected cells. We
show that ROS/RNS generated during toxin exposure leads toasal levels of SNO-MEF2C compared to corrected hNs, pesticides increased
negative control in the absence of ascorbate (Asc) (J).
A with posthoc Tukey; n = 3.
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Figure 6. MEF2C and Pesticides Regulate PGC1a Protein Expres-
sion In Vivo
(A) PGC1a protein expression in WT and A53T mutant mouse brain in the
presence and absence of PQ/MB exposure.
(B) PQ/MB increases SNO-MEF2C expression in WT mouse brain by biotin
switch assay.
(C) Quantification of SNO-MEF2C inWTmouse brain. Values are mean + SEM.
**p < 0.01, by t test; n = 3.
1360 Cell 155, 1351–1364, December 5, 2013 ª2013 Elsevier Inc.increased sulfonation/S-nitrosylation of the antiapoptotic tran-
scription factor MEF2C and that NO contributes to cell death
because inhibition of NOS with L-NAME attenuated the damage.
Causality of SNO-MEF2 in this form of cell death is implicated by
rescue of neurons with the nonnitrosylatable MEF2C(C39A)
mutant construct.
A number of aberrantly S-nitrosylated proteins have been
implicated in neurodegenerative disorders and may contribute
to specific disease pathology (Nakamura et al., 2013). In support
of this notion in PD, gene ontology clustering after genetic
profiling of A53T mutant hNs relative to corrected cells showed
aberrations in biological processes related to metabolism of
nitrogen-containing compounds. Additionally, this analysis
identified downregulation of a number of targets of the prosur-
vival/pro-DA neurogenic transcription factor MEF2 (Leifer et al.,
1993; Mao et al., 1999; Okamoto et al., 2000, 2002; Li et al.,
2008a,b; Cho et al., 2011), suggesting possible involvement of
MEF2 in neuronal damage in PD. MEF2 isoforms localize in
part to mitochondria and influence oxidative phosphorylation
(OXPHOS) (She et al., 2011). Hence, MEF2 is an excellent candi-
date for a protein whose dysfunction might have a major impact
on DA neuron homeostasis. Supporting this hypothesis, in the
present study, we show that mitochondrial toxins such as
pesticides induce damage in DA neuronal cells at least in part
by inhibiting MEF2C activity via S-nitrosylation, and the nonoxi-
dizable form of MEF2 rescues this damage.
Our bioinformatics analysis of potential MEF2-binding sites
in the neuronal genome identified several potential targets
whereby dysfunctional MEF2 might elicit mitochondrial damage
and neuronal death. PGC1a was among the targets that we
experimentally validated by ChIP-qPCR analyses. Interestingly,
prior work had suggested that PGC1a and MEF2 were function-
ally linked (Czubryt et al., 2003; Handschin et al., 2003). As a
master regulator of mitochondrial bioenergetics and oxidative
metabolic programs, transgenic expression of PGC1a in DA
neurons can protect them from MPTP-induced death (Mudo`
et al., 2012). Moreover, the Global PD Gene Expression con-
sortium identified PGC1a as a therapeutic target for early
intervention in PD (Zheng et al., 2010). Consistent with these
findings, we show that posttranslational redox modification
of MEF2C contributes to mitochondrial dysfunction and DA
neuronal apoptosis by decreasing PGC1a expression. Given
the important regulatory influence of MEF2C on PGC1a and
the fact that even short exposures to mitochondrial toxins impair
this effect, oxidative/nitrosative stress mediated by sulfonation/
S-nitrosylation of MEF2C may well be an early, critical event in
PD pathogenesis. Although these results identify disruption of
the MEF2C-PGC1a pathway as a potential contributor to DA
neuronal demise in PD, they do not exclude additional pathways
either involving other MEF2 isoforms or independent of MEF2
altogether from being important.
An intriguing observation in the present study is the finding
that human DA neurons carrying the A53T SNCA mutation
display increased vulnerability to mitochondrial toxin-induced(D) PGC1a protein levels are reduced in MEF2C+/– and MEF2C conditional
knockout mouse brains.
Figure 7. Activation of MEF2C Transcriptional Network Rescues A53T Mutant hNs from Mitochondrial Toxin-Evoked Death
(A) L-NAME partially blocks PQ/MB-induced death in A53T mutant hiPSC-derived hNs. **p < 0.01 by ANOVA with posthoc Tukey; n = 6.
(B) TUNEL reactivity in A53T hNs exposed to mitochondrial toxins PQ and MB following overexpression of MEF2C (with or without 1 mM L-NAME) or PGC1a.
WT MEF2C, mutant MEF2C(C39A), and PGC1a rescue from PQ/MB-induced apoptosis relative to empty vector (EV)-expressing cells. DIV, 25; blue, DAPI;
scale bar, 10 mm.
(C) Quantification of data in (C). Values are mean + SEM. **p < 0.01, *p < 0.05 by ANOVA with posthoc Tukey or Fisher PLSD; n = 6.
(D) TUNEL reactivity in A53T hNs exposed to PQ and MB following pretreatment with the MEF2 activator Isoxazole (10 mM). Isoxazole rescued from rotenone- or
PQ/MB-induced apoptosis. DIV, 35; blue, DAPI; scale bar, 10 mm.
(E) Quantification of data in (D). Values are mean + SEM. *p < 0.05 by t test; n = 3.
(F) In human A9-type DA neurons, MEF2C drives MEF2 target genes, including PGC1a expression, which in turn promotes mitochondrial biogenesis,
mitochondrial respiration, and neuronal health (i). When SNCA is mutated (A53T) in familial PD, higher steady-state levels of RNS result in the S-nitrosylation of
MEF2C under basal conditions. Resulting inhibition of MEF2C transcriptional activity decreases MEF2 target gene expression, including PGC1a (dashed line),
with consequent impairment of mitochondrial respiration and disruption of neuronal function (ii). Combined effect of mitochondrial stress due to A53T SNCA and
exposure to mitochondrial toxins produces a dramatic increase in RNS and ROS over basal conditions, resulting in increased S-nitrosylation and/or sulfonation
of MEF2C and further decrease in MEF2C activity. The decreased MEF2C activity leads to further inhibition of MEF2 target gene transcription, including PGC1a,
and consequently a more profound drop in mitochondrial biogenesis and respiration, culminating in neuronal cell death (width of red lines indicates magnitude
of effect) (iii).
See also Figure S6.cell death. This result suggests that the mutant background
may facilitate induction of PD by environmental toxins, support-
ing a ‘‘two-hit hypothesis.’’ In accord with our findings on
human neurons, prior studies in rodents had suggested that
aberrant expression of a-syn increases the vulnerability of
SNpc neurons to the neurotoxic effects of PQ/MB (Thiruchel-
vam et al., 2004; Norris et al., 2007). Mutation of a-syn pro-
motes oligomerization and aggregation, leading to formation
of Lewy bodies/neurites (Lashuel et al., 2013), as observed in
A53T hNs. Oligomerization or aggregation of several proteins,including a-syn, is associated with aberrant accumulation of
RNS/ROS (Giasson et al., 2000; Gregersen and Bross 2010;
Schildknecht et al., 2013). Thus, mutant a-syn neurons are
exposed to oxidative/nitrosative stress under basal conditions.
Accordingly, we observed an increase in the basal level of
SNO-MEF2C in A53T hNs compared to corrected controls.
These observations may thus help to explain the increased
vulnerability of the A53T mutant neurons to nitrosative damage
after mitochondrial toxin exposure compared to isogenic cor-
rected controls.Cell 155, 1351–1364, December 5, 2013 ª2013 Elsevier Inc. 1361
In summary, in A53T SNCAmutant hNs, we identify the MEF2-
PGC1a transcriptional pathway as a contributor to neuronal
damage. Using hiPSC-derived A9 neurons and high-throughput
screening studies, we show that this pathway represents a target
for potential therapeutic intervention in PD. Finally, we provide a
new molecular mechanism whereby genes and environment
(GxE) can interact to contribute to the PD phenotype in human
cells. Namely, mitochondrial toxins, represented by environ-
mental pesticides, are shown to induce nitrosative/oxidative
stress that inhibits MEF2C activity via S-nitrosylation (or possibly
sulfonation) of Cys39 in theMEF2CDNA-binding domain. In turn,
this attenuates PGC1a expression and thus the neuroprotective
effect of this transcriptional coactivator. In the future, therapeu-
tics aimed at counteracting the aberrant redox pathway that in-
hibits MEF2C transcriptional activity may prove effective in
combating neuronal injury in PD.
EXPERIMENTAL PROCEDURES
hiPSC/hESC Culture and A9 DA Neuronal Differentiation
hiPSCs/hESCs were cultured as previously described, with details of this pro-
cedure and A9 DA neuronal differentiation provided in the Extended Experi-
mental Procedures.
Measurements of Oxygen Consumption Rate
Oxygen consumption rate was analyzed in day 35 hNs using an XF24-3 Extra-
cellular Flux Analyzer (Seahorse Biosciences), as described in the Extended
Experimental Procedures.
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling,
Active Caspase-3 Assessment, and Image Analysis
For evaluation of apoptosis, cells exposed to toxins or vehicle were subjected
to terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
assay, immunocytochemistry for active (cleaved) caspase-3, and immunolab-
eling for neuronal markers. Details are provided in the Extended Experimental
Procedures.
Global Gene Expression Analysis
Expression profiling was performed using the One-Color Microarray Gene
Expression Platform with Illumina beadchip human-HT-12 v4. Transcription
factor targets enriched in A53T relative to corrected hNs are listed in Table
S2, and those not enriched are listed in Table S3. Details of data analysis
are in the Extended Experimental Procedures. Data available from the Gene
Expression Omnibus under accession number GSE46798.
Detection of ROS/RNS and Redox-Modified Proteins
MitoSOX detection of superoxide and DAF-FM assay of NO were performed
as permanufacturer’s instructions (Invitrogen, CA). Biotin switch assay (Jaffrey
et al., 2001; Uehara et al., 2006) was used to detect S-nitrosylated cysteine
residues in MEF2C protein. Details, with Griess and DCP-Bio assays, are pro-
vided in the Extended Experimental Procedures.
Reporter Gene Assay
Cells were transfected via Lipofectamine 2000 (Invitrogen) with MEF2 or
PGC1a luciferase reporter and Renilla luciferase control vector. Analysis
used Dual-Glo luciferase assay kit (Promega). See the Extended Experimental
Procedures.
Chromatin Immunoprecipitation
ChIP assays were performed using the ChIP-IT EXPRESS assay kit (Active
Motif, CA). Immunoprecipitations were performed using anti-MEF2C antibody
(Santa Cruz). Input and ChIP DNA were analyzed by qPCR using Stratagene
Mx3000P (see the Extended Experimental Procedures).1362 Cell 155, 1351–1364, December 5, 2013 ª2013 Elsevier Inc.Small-Molecule Screening and Testing of ‘‘Hit’’ Compounds
MEF2 luciferase reporter screen was performed in human neuronal context
against a chemical library for MEF2 activators (see the Extended Experimental
Procedures).
Statistical Analysis
Data represent at least three independent experiments, presented as
mean ± SEM. Statistical significance was ascertained by t test or two-way
ANOVA with appropriate posthoc testing; p < 0.05 was considered significant.
ACCESSION NUMBERS
mRNA expression data have been deposited in Gene Expression Omnibus un-
der accession number GSE46798.
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